Management of the axilla post‐neoadjuvant chemotherapy in node positive breast cancer: Can the combination of axillary ultrasound and tumor biomarkers improve patient selection for sentinel node biopsy?

The authors examined the utility of axillary ultrasound (aUS) and primary tumor biomarker profile in identifying patients with axillary complete pathological response. Topics mentioned include the use of the Picture Archiving and Communication System software to measure cortical thickness, association between aUS lymph node appearances, tumor biomarker profile, and histological LN status post-neoadjuvant chemotherapy, and absence of a fatty hilum on aUS.